Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pulse Biosciences, Inc - Common Stock
(NQ:
PLSE
)
52.64
-1.17 (-2.17%)
Delayed Quote
Updated: 10:12 AM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pulse Biosciences, Inc - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 09, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
October 08, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
October 07, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
September 15, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
August 06, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
July 30, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
July 29, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
July 21, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 15, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
June 10, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
May 27, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
May 12, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
May 08, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
May 04, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
April 25, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
April 20, 2026
From
Pulse Biosciences
Via
Business Wire
Pulse Biosciences to Host Analyst Event on April 25, 2026
April 17, 2026
From
Pulse Biosciences
Via
Business Wire
Pulse Biosciences Strengthens Executive Leadership Team
April 09, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
April 07, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
April 02, 2026
From
Pulse Biosciences, Inc
Via
Business Wire
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
March 17, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
March 12, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
March 09, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
March 05, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
March 04, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
February 20, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
February 19, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
